Ajanta Pharma Q2 Results 2025 Highlights: Net Profit Surged by 20.19% & Revenue Up 14.08% YoY

Ajanta Pharma Q2 Results FY26: During Q2 FY26,  Ajanta Pharma's profit increased 20.19% YoY, while revenue increased by 14.08% YoY. The company posted robust numbers, with Q2 PAT at ₹260.19 crores and revenue at ₹1,353.73 crores. Ajanta Pharma showed its Q2 results on 3rd November 2025.  

Ajanta Pharma Q2 Results FY26: Extracts of FY25 & FY26

Particulars	Consolidated Figures		Standalone Figures
	30th Sep 2025	30 Sept 2024	30th Sept 2025	30th Sept 2024
Revenue from Operations	₹1,353.73	₹1,186.64	₹1,220.24	₹1,128.91
Profit Before Tax (PBT)	₹387.17	₹330.65	₹364.62	₹343.25
Profit After Tax (PAT)	₹260.19	₹216.48	₹249.53	₹234.98

Ajanta Pharma Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Ajanta Pharma clocked Q2 FY26 consolidated revenue of ₹1,353.73 crores vs ₹1,186.64 crores. 
• On the profit front, Ajanta Pharma earned a consolidated PAT of₹260.19 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹216.48 crore.
• According to the consolidated figures, Ajanta Pharma's quarterly PAT increased by 20.19% YoY, while revenue increased by 14.08%.
• Ajanta Pharma clocked Q2 FY26 standalone revenue of ₹1,220.24 crores vs ₹1,128.91 crores. 
• On the profit front,  Ajanta Pharma earned a standalone PAT of ₹249.53 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹234.98 crore.
• According to the standalone figures,  Ajanta Pharma's quarterly PAT increased by 6.19% YoY, while revenue increased by 8.09%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

About  Ajanta Pharma Limited

Ajanta Pharma Limited was established in 1973, with its headquarters in Mumbai, India.  it is a special pharmaceutical company that develops, manufactures, and markets finished pharmaceutical dosage forms. The company has a global presence in over 30 countries across Asia and Africa. The company has focused on branded generics in various therapeutic segments. The company also has a generic business in the U.S. market, with a portfolio of niche and complex products. Key strengths include a substantial research and development (R&D) team, with over 850 scientists, and seven manufacturing facilities in India and Mauritius.    

Ajanta Pharma Share Price Performance 

On the opening bell on 4th November 2025,  Ajanta Pharma shares opened at ₹2,558.90 per share. However, the initial gains have since eroded, and Ajanta Pharma shares are trading at ₹2,594.50 per share, higher than the opening price.    

Considering the long-term achievements, Ajanta Pharma shares have yielded returns of approximately 0.31% over the past 6 months, and 1-year returns stand at -13.07%. Over the maximum timeframe, Ajanta Pharma shares delivered a 16,355.93% return to investors. 

What Analysts Expect Post Q2 Results?

Following Ajanta Pharma's robust Q2 results for FY26, analysts expect its share price to rise. According to analysts, Ajanta Pharma's share price could reach ₹2,690.20 per share in the coming year and, in a downturn, could hit ₹2,550.20 per share. However, one must ignore stock market volatility and invest in  Ajanta Pharma shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here